Efficacy and safety of icotrokinra (JNJ2113) for moderate-to-severe plaque psoriasis: a systematic review and metaanalysis of randomized controlled trials
2026· Annals of Middle Eastern Medicine· 0 citations
TL;DR
Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs and offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time.
Abstract
Icotrokinra (JNJ-2113) is a first-in-class targeted oral peptide that selectively binds to the interleukin-23 (IL-23) receptor and blocks IL-23 signaling. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of Icotrokinra to assess its efficacy and safety versus control in moderate-to-severe plaque psoriasis. We performed a PRISMA-adherent systematic literature search across Scopus, PubMed, and Web of Science from their inception up to January 2026. Screening, data extraction, and risk of bias assessment were made by two independent authors. A meta-analysis was conducted in R with sensitivity and subgroup analyses. We included four studies comprising five RCTs. Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs. For Investigator’s Global Assessment (IGA) 0/1, benefit was evident by week 2 (risk ratios (RR) = 3.24%, 95% confidence interval (CI) 1.01–10.46) and remained consistent through week 16 (RR = 7.35%, 95% CI 5.67–9.54), with an overall pooled effect RR = 7.31 (95% CI 6.25–8.55). Complete clearance (IGA 0) emerged from week 8 (RR = 23.65%, 95% CI 6.74–82.95), overall RR = 12.44 (95% CI 6.88–22.51). PASI 75 overall RR = 6.74 (95% CI 5.75–7.91); PASI 90 RR = 14.38; PASI 100 RR = 11.17. PSSD symptom 0 at week 16: 256/1226 vs 9/551 (RR=9.62%, 95% CI 5.14–18.01). Icotrokinra offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time; by week 8, complete clearance became significantly more frequent with icotrokinra. Safety outcomes were comparable between icotrokinra and placebo, and there was no meaningful increase in serious adverse events.
Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients’ quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effecti...
Z. Siddiqi, Sume Rubab, Faisal Jamal Alashkar et al.· JMA Journal· 0 citations
TOPIC
Teprotumumab is the first FDA-approved biologic for moderate-to-severe thyroid eye disease (TED). Although efficacy has been established in randomized controlled trials (RCTs), real-world studies (RWS) have reported different efficacy and safety patterns, supporting an updated synthesis.
CLINICAL RELEVANCE
A co...
Ai-Min Sun, Xing Wang, Jun-Yu Wang et al.· American journal of ophthalm...· 1 citation
Objective: Mirikizumab, a p19-directed anti-interleukin-23 monoclonal antibody, has been evaluated as induction and maintenance therapy for moderately to severely active ulcerative colitis (UC). We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials to quantify its efficacy and safe...
G. Dağcı, A. Sarıca, B. F. Ağargün et al.· Journal of Enterocolitis· 0 citations
BACKGROUND
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by esophageal dysfunction and eosinophilic inflammation. Comparative efficacy and safety of therapies remain uncertain.
OBJECTIVE
To compare efficacy and safety of treatments for EoE in children and adults.
METHODS
We condu...
Y. Roldan, I. Silang, D. Rayner et al.· Journal of Allergy and Clini...· 0 citations
Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs) driven by the interleukin-23/Th17 pathway. Guselkumab, a selective interleukin-23p19 monoclonal antibody, has shown promise in phase II/III trials. This systematic review and meta-analysis aimed to synthesize its efficacy and safety v...
Z. Shahid, M. Azam, Ahila Ali et al.· European Journal of Gastroen...· 0 citations
Objectives: To evaluate the clinical efficacy and safety of Bazhen Decoction for chemotherapy-induced leukopenia, we analyzed randomized controlled trials (RCTs) in which Palmul-tang (Bazhen Decoction) was administered to patients with chemotherapy-induced leukopenia.Methods: Nine databases were searched for RCTs publi...
Ah-young Choi, Jung-Hun Lee, Sung-mo Kim et al.· The Journal of Internal Kore...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.